Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trypanosoma cruzi | 16 | 2023 | 157 | 4.230 |
Why?
|
| Chagas Disease | 11 | 2023 | 104 | 2.830 |
Why?
|
| RNA, Small Interfering | 4 | 2025 | 436 | 2.110 |
Why?
|
| Thrombospondin 1 | 4 | 2022 | 23 | 1.800 |
Why?
|
| Protozoan Proteins | 6 | 2020 | 191 | 1.160 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2023 | 9 | 0.950 |
Why?
|
| Parasites | 1 | 2026 | 38 | 0.920 |
Why?
|
| Premature Birth | 2 | 2023 | 95 | 0.840 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2022 | 60 | 0.830 |
Why?
|
| Myocardium | 2 | 2025 | 263 | 0.750 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2022 | 24 | 0.740 |
Why?
|
| beta Catenin | 1 | 2022 | 78 | 0.690 |
Why?
|
| Endothelial Cells | 2 | 2022 | 329 | 0.660 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 749 | 0.650 |
Why?
|
| Myoblasts | 1 | 2020 | 30 | 0.650 |
Why?
|
| Myocytes, Cardiac | 3 | 2025 | 183 | 0.590 |
Why?
|
| Epithelial Cells | 3 | 2018 | 434 | 0.540 |
Why?
|
| Animals | 22 | 2026 | 16992 | 0.540 |
Why?
|
| Colon | 1 | 2018 | 120 | 0.530 |
Why?
|
| Antineoplastic Agents | 1 | 2026 | 1019 | 0.530 |
Why?
|
| Proteome | 1 | 2018 | 152 | 0.520 |
Why?
|
| Phosphoproteins | 1 | 2018 | 206 | 0.510 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2016 | 8 | 0.480 |
Why?
|
| Breast Neoplasms | 1 | 2026 | 1723 | 0.430 |
Why?
|
| Gene Regulatory Networks | 2 | 2016 | 149 | 0.410 |
Why?
|
| Calreticulin | 1 | 2012 | 8 | 0.380 |
Why?
|
| Humans | 25 | 2026 | 43102 | 0.360 |
Why?
|
| Gene Expression Regulation | 3 | 2025 | 1070 | 0.350 |
Why?
|
| RNA Interference | 3 | 2010 | 247 | 0.350 |
Why?
|
| Cell Membrane | 3 | 2013 | 403 | 0.350 |
Why?
|
| Mice | 9 | 2023 | 6644 | 0.340 |
Why?
|
| Heart | 2 | 2023 | 184 | 0.330 |
Why?
|
| Proteomics | 2 | 2025 | 378 | 0.320 |
Why?
|
| Coronary Vessels | 1 | 2010 | 92 | 0.310 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 91 | 0.300 |
Why?
|
| Onchocerciasis | 3 | 2007 | 7 | 0.260 |
Why?
|
| Host-Parasite Interactions | 2 | 2026 | 79 | 0.250 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2025 | 20 | 0.240 |
Why?
|
| Laminin | 1 | 2006 | 58 | 0.240 |
Why?
|
| Fish Oils | 2 | 2023 | 13 | 0.240 |
Why?
|
| Blood Proteins | 1 | 2025 | 77 | 0.230 |
Why?
|
| Gene Silencing | 1 | 2006 | 154 | 0.230 |
Why?
|
| Rats | 4 | 2022 | 3735 | 0.220 |
Why?
|
| Wound Healing | 1 | 2025 | 88 | 0.220 |
Why?
|
| Cell Communication | 1 | 2025 | 114 | 0.220 |
Why?
|
| Helminth Proteins | 2 | 2002 | 26 | 0.210 |
Why?
|
| Oxadiazoles | 2 | 2015 | 15 | 0.210 |
Why?
|
| Onchocerca | 2 | 2002 | 5 | 0.210 |
Why?
|
| Signal Transduction | 2 | 2025 | 2157 | 0.200 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 26 | 0.200 |
Why?
|
| Myocardial Infarction | 1 | 2025 | 247 | 0.190 |
Why?
|
| Pneumonia | 1 | 2023 | 61 | 0.180 |
Why?
|
| Endothelium | 1 | 2022 | 28 | 0.180 |
Why?
|
| Fibroblasts | 1 | 2023 | 281 | 0.170 |
Why?
|
| Animals, Newborn | 1 | 2022 | 352 | 0.170 |
Why?
|
| alpha-Defensins | 2 | 2013 | 22 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2021 | 47 | 0.160 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 53 | 0.160 |
Why?
|
| Female | 10 | 2026 | 24698 | 0.160 |
Why?
|
| Diet | 2 | 2023 | 826 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 704 | 0.150 |
Why?
|
| Trans-Activators | 1 | 2020 | 192 | 0.150 |
Why?
|
| Cloning, Molecular | 2 | 2012 | 314 | 0.150 |
Why?
|
| Antigens, Helminth | 3 | 2007 | 34 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 213 | 0.140 |
Why?
|
| Mice, Knockout | 1 | 2022 | 1035 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 241 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 561 | 0.130 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1621 | 0.120 |
Why?
|
| Imidazoles | 2 | 2015 | 142 | 0.120 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2015 | 17 | 0.110 |
Why?
|
| Fibrosis | 1 | 2016 | 169 | 0.110 |
Why?
|
| Models, Biological | 1 | 2018 | 712 | 0.110 |
Why?
|
| Antiprotozoal Agents | 1 | 2015 | 31 | 0.110 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 1 | 2014 | 8 | 0.110 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 98 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2014 | 62 | 0.110 |
Why?
|
| Benzamides | 1 | 2015 | 81 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2014 | 165 | 0.100 |
Why?
|
| Capsid Proteins | 1 | 2014 | 76 | 0.100 |
Why?
|
| Onchocerca volvulus | 2 | 2007 | 5 | 0.100 |
Why?
|
| Flagella | 1 | 2013 | 32 | 0.100 |
Why?
|
| Locomotion | 1 | 2013 | 105 | 0.100 |
Why?
|
| Life Cycle Stages | 1 | 2012 | 29 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 127 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2012 | 107 | 0.090 |
Why?
|
| Cytokines | 1 | 2016 | 678 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 458 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1869 | 0.080 |
Why?
|
| Male | 6 | 2025 | 23409 | 0.080 |
Why?
|
| Casein Kinase II | 2 | 2008 | 17 | 0.080 |
Why?
|
| Neuraminidase | 2 | 2008 | 9 | 0.080 |
Why?
|
| Neoplasms | 1 | 2021 | 1377 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 310 | 0.070 |
Why?
|
| Ligands | 1 | 2010 | 388 | 0.070 |
Why?
|
| Protein Binding | 1 | 2012 | 1082 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 1596 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2010 | 536 | 0.070 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 98 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 592 | 0.060 |
Why?
|
| Myoblasts, Cardiac | 1 | 2006 | 4 | 0.060 |
Why?
|
| Serologic Tests | 2 | 2007 | 45 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 458 | 0.060 |
Why?
|
| Antigens, Protozoan | 1 | 2006 | 74 | 0.060 |
Why?
|
| Immunoglobulin G | 2 | 2007 | 259 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2025 | 74 | 0.060 |
Why?
|
| Ventricular Remodeling | 1 | 2025 | 61 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 518 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 611 | 0.060 |
Why?
|
| Antibodies, Helminth | 2 | 2002 | 24 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 440 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2025 | 280 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2002 | 455 | 0.050 |
Why?
|
| Fathers | 1 | 2023 | 38 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2006 | 561 | 0.050 |
Why?
|
| Base Sequence | 2 | 2002 | 983 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 694 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 1081 | 0.050 |
Why?
|
| Geography | 1 | 2002 | 110 | 0.050 |
Why?
|
| DNA Primers | 1 | 2002 | 294 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2002 | 115 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 972 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 492 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 1175 | 0.040 |
Why?
|
| Pregnancy | 1 | 2023 | 1772 | 0.030 |
Why?
|
| HLA-DP Antigens | 1 | 1996 | 1 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1997 | 189 | 0.030 |
Why?
|
| Biotransformation | 1 | 2015 | 69 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 99 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 386 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2015 | 75 | 0.030 |
Why?
|
| Aged | 2 | 2025 | 8214 | 0.030 |
Why?
|
| Child | 1 | 2023 | 3443 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 240 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2013 | 40 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 1542 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 506 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 570 | 0.020 |
Why?
|
| Africa | 2 | 2007 | 82 | 0.020 |
Why?
|
| Molecular Weight | 2 | 2006 | 168 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 260 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1992 | 34 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 368 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1992 | 306 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 1180 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 549 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1604 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2008 | 48 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 64 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 35 | 0.020 |
Why?
|
| Vacuoles | 1 | 2007 | 22 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 125 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 236 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 249 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 160 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 154 | 0.020 |
Why?
|
| Hela Cells | 1 | 2007 | 376 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2006 | 219 | 0.010 |
Why?
|
| Virulence Factors | 1 | 2006 | 125 | 0.010 |
Why?
|
| Adolescent | 3 | 2007 | 6081 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1285 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 986 | 0.010 |
Why?
|
| Middle Aged | 3 | 2007 | 12222 | 0.010 |
Why?
|
| Adult | 3 | 2007 | 13872 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 1997 | 29 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 249 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 296 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1992 | 238 | 0.010 |
Why?
|